MAZE vs ZYME
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MAZE · Maze Therapeutics$31.37 ▼ 3.27%
ZYME · Zymeworks$26.14 ▼ 2.68%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MAZE -14.4%
- ZYME +4.6%
Head to head
| Metric | MAZE | ZYME |
|---|---|---|
| Price | $31.37 | $26.14 |
| Change today | ▼ 3.27% | ▼ 2.68% |
| Market cap | $1.72B | $1.81B |
| Return, 3 months | +6.0% | -9.1% |
| Return, year to date | -24.3% | -0.7% |
| Return, 1 year | -13.5% | +8.8% |
| P/E (TTM) | – | 49.3 |
| P/B | 4.0 | 7.0 |
| P/E percentile vs own 5y | 44th | 100th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +828.7% |
| Net profit growth (YoY) | -59.4% | +986.1% |
| Gross margin | – | – |
| Operating margin | -820.8% | 16.6% |
| Net margin | -757.4% | 16.3% |
| Return on equity | -37.5% | 15.0% |
| Analyst target vs. price | +96.9% | +60.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 47 | 43 |
| 30-day volatility | 58.6% | 56.5% |
| Max drawdown, 1 year | -56.8% | -23.6% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ZYME is the largest of the group by market value.
- ZYME has returned the most over the past year.
- ZYME keeps the most profit per dollar of sales.
- ZYME has been the calmest stock over the last 30 days.